Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS ...

DMTs slow the progression of multiple sclerosis and reduce relapse severity. Starting DMTs soon after diagnosis can help delay disability and disease progression. Injectable DMTs, like beta interferon ...

The Global Multiple Sclerosis Treatment Market Report 2025 provides a comprehensive analysis of market trends, multiple sclerosis prevalence, patient population, disease burden, treatment adoption, ...

The FDA agreed to speed its review of a Roche drug the developer says could be the first oral high-efficacy therapy approved ...

A trial will test whether noninvasive nerve stimulation paired with hand rehab can improve function and support myelin repair ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that causes disruptions in the flow of information within the brain and between the brain and body, eventually causing ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million people estimated to be living with the disease worldwide. As MS is an ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses ...

A study of 509 people newly diagnosed with MS found only small differences after two years, based on the first treatment they used. People taking B-cell treatments had fewer MS attacks and a small ...